Multivariate analysis: risk factors for damage accrual over the follow-up
| B | p Value | OR | 95% CI | ||
|---|---|---|---|---|---|
| Unremitted disease | 0.927 | 0.008 | 2.527 | 1.279 | 4.992 |
| High-dose intravenous methylprednisolone | 0.856 | 0.026 | 2.355 | 1.107 | 5.009 |
| Pre-existing organ damage | 0.298 | 0.355 | 1.348 | 0.716 | 2.537 |
| Glomerulonephritis | −0.349 | 0.353 | 0.705 | 0.337 | 1.474 |
| NP-SLE | 0.795 | 0.111 | 2.215 | 0.834 | 5.883 |
| Vasculitis | 0.366 | 0.453 | 1.442 | 0.555 | 3.746 |
| Haematological manifestations | −0.034 | 0.914 | 0.966 | 0.517 | 1.807 |
| Skin involvement | 0.159 | 0.708 | 1.172 | 0.511 | 2.687 |
| Gender (female) | −0.434 | 0.331 | 0.648 | 0.271 | 1.552 |
| Low C3 or C4 | −0.910 | 0.095 | 0.403 | 0.138 | 1.171 |
| Anti-dsDNA Abs | 0.513 | 0.281 | 1.671 | 0.657 | 4.250 |
| Constant | −1.138 | 0.048 | 0.321 | ||
Significant variables are given in bold. Anti-dsDNA Abs, anti-double-stranded DNA antibodies; C3/C4, complement components; NP-SLE, neuropsychiatric SLE; SLE, systemic lupus erythematosus.